Physician profile
Mindy Jan
NPI 1902804974
$6,563.70
in general payments reported to CMS, 2019-2025
34 companies · $1,236 in 2025
The $1,236 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $815 · 2020: $379 · 2021: $580 · 2022: $999 · 2023: $1,297 · 2024: $1,257 · 2025: $1,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,790.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,114.70 | 2019-2025 | Lokelma, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $774.70 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $550.53 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $489.49 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Fresenius USA Marketing, INC. | $407.27 | 2019-2025 | Velphoro, Velphoro |
| Novo Nordisk INC | $384.70 | 2022-2025 | Ozempic, Wegovy, Rivfloza |
| Baxter Healthcare | $236.47 | 2020-2024 | |
| Glaxosmithkline, LLC. | $217.43 | 2021-2024 | Benlysta, Jesduvroq |
| Vifor Pharma, INC. | $211.75 | 2019-2023 | Veltassa |
| Alexion Pharmaceuticals, INC. | $189.33 | 2022-2023 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $177.54 | 2023-2025 | |
| Akebia Therapeutics INC | $162.35 | 2022-2025 | Vafseo, Auryxia |
| Janssen Pharmaceuticals, INC | $155.18 | 2019 | |
| Vantive US Healthcare LLC | $149.33 | 2025 | Renal - Pd |
| Horizon Therapeutics Plc | $145.23 | 2019-2023 | Krystexxa |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $143.04 | 2023 | Gattex, Livtencity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.00 | 2024-2025 | Jardiance |
| Travere Therapeutics, INC. | $141.06 | 2021-2024 | |
| Calliditas Therapeutics US INC. | $101.69 | 2022-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $93.78 | 2020-2025 | Terlivaz, Acthar |
| Alnylam Pharmaceuticals INC. | $74.78 | 2023-2025 | Givlaari |
| Ardelyx, INC. | $68.83 | 2024-2025 | Ibsrela |
| Daiichi Sankyo INC. | $68.32 | 2020-2025 | Injectafer |
| Cormedix INC. | $49.19 | 2024-2025 | Defencath, Defencath |
| Aurinia Pharma U.S., INC. | $48.09 | 2021-2022 | |
| Nxstage Medical, INC. | $43.61 | 2020-2024 | |
| Opko Pharmaceuticals, LLC | $39.13 | 2019 | |
| Veloxis Pharmaceuticals, INC. | $38.76 | 2024 | Envarsus |
| Cumberland Pharmaceuticals, INC. | $28.99 | 2019-2020 | |
| Lilly USA, LLC | $28.19 | 2023-2025 | Jardiance |
| Lundbeck LLC | $23.73 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $23.64 | 2024 | |
| Ani Pharmaceuticals, INC. | $21.56 | 2025 | Purified Cortrophin Gel |
| Chiesi USA, INC. | $18.31 | 2024 | Elfabrio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mindy Jan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.